Theratechnologies Inc.TSX: TH

PRESS CONFERENCE - Theratechnologies Inc. - Invitation to Media

· Issued by Theratechnologies Inc.
MONTREAL, April 11 /CNW TELBEC/ - Theratechnologies (TSX: TH) recently
received authorization from the Food and Drug Administration (FDA) in United
States to proceed to Phase III with its lead compound, ThGRF (TH9507), in HIV-
associated lipodystrophy. Phase III is the final stage of testing prior to
submitting a product for market approval. To mark this occasion, media
representatives are invited to meet members of Theratechnologies' management
team as they will give an update on ThGRF Phase III program. The press
conference will also be an opportunity to meet Dr. Julian Falutz, Assistant
Professor, McGill University Medical School, and leading authority on HIV-
associated lipodystrophy. Dr. Falutz is lead investigator for Canada in
Theratechnologies' lipodystrophy study. The Annual Meeting of Shareholders
will be held immediately after the press conference.


What:         Press Conference and Annual General Meeting of Shareholders

Who:          Mr. A. J. de GrandprDe, Chairman of the Board
              Mr. Yves Rosconi, President and Chief Executive Officer
              Mr. Luc Tanguay, Senior Executive Vice President
               and Chief Financial Officer

Special guest:  Dr. Julian Falutz, Director, HIV Metabolic Clinic,
--------------  MontrDeal General Hospital, Assistant Professor, McGill
                University Medical School, and Lead Investigator for
                Canada

Where:        Centre Mont-Royal (corner of Sherbrooke Street)
              2200 Mansfield Street
              Salon l'International I-II, 2nd Floor
              Montreal

When:         Wednesday, April 13, 2005
              Press conference at 9:00 am
              Annual meeting at 10:00 am


About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (completed Phase II) targets HIV-associated lipodystrophy. Other
clinical programs are investigating wasting associated with chronic disease
and type 2 diabetes. Theratechnologies' website is located at
www.theratech.com .

Theratechnologies Inc. on 6ix

Later from Theratechnologies

All Theratechnologies news releases